6642.5000 0.00 (0.00%)
NSE Jan 07, 2026 15:31 PM
Volume: 423.9K
 

Axis Direct
While Q3 EBITDA was inline with estimate, PAT of Rs 2.68bn was 10% below our estimate due to higher taxes. Revenue growth was muted at 13% YoY (9M was 14% YoY, 10% in cc terms). Divi'sguided for 10- 15% cc revenue growth for FY17/18 vs.15% earlier, given delay in adding capacities (Vizagand Kakina..
Divi's Laboratories Ltd. is trading above all available SMAs
More from Divi's Laboratories Ltd.
Recommended